Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product containing dextrose and methylprednisolone acetate. Dextrose is a simple sugar (glucose) commonly used as an energy source or diluent in pharmaceutical preparations. Methylprednisolone acetate is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. The combination may be compounded for specific clinical uses, such as intra-articular injections for inflammatory joint conditions, where dextrose can serve as a diluent or adjunct to the steroid component. Methylprednisolone acetate acts by binding to glucocorticoid receptors, modulating gene expression, suppressing pro-inflammatory cytokines, and inhibiting immune cell activity[1][6][7]. Dextrose does not have direct anti-inflammatory effects but may provide osmotic support or serve as a vehicle.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrose + methylprednisolone acetate.